Growth Metrics

Day One Biopharmaceuticals (DAWN) Cash from Investing Activities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash from Investing Activities for 4 consecutive years, with $167.5 million as the latest value for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 162.11% year-over-year to $167.5 million; the TTM value through Dec 2025 reached $174.6 million, up 175.61%, while the annual FY2025 figure was $174.6 million, 175.61% up from the prior year.
  • Cash from Investing Activities was $167.5 million for Q4 2025 at Day One Biopharmaceuticals, up from $13.5 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $167.5 million in Q4 2025, with the low at -$269.6 million in Q4 2024.
  • Historically, Cash from Investing Activities has averaged -$11.4 million across 4 years, with a median of $6.7 million in 2022.
  • Biggest YoY gain for Cash from Investing Activities was 1474.66% in 2023; the steepest drop was 74520.0% in 2023.
  • Over 4 years, Cash from Investing Activities stood at -$2.2 million in 2022, then soared by 1474.66% to $30.4 million in 2023, then crashed by 987.56% to -$269.6 million in 2024, then skyrocketed by 162.11% to $167.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $167.5 million in Q4 2025, $13.5 million in Q3 2025, and $26.3 million in Q2 2025.